Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Above 50 Day Moving Average - Should You Sell?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Get Free Report) passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.22 and traded as high as $2.25. Oramed Pharmaceuticals shares last traded at $2.11, with a volume of 141,792 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen downgraded Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th.

Oramed Pharmaceuticals Stock Performance

The company has a market capitalization of $87.83 million, a price-to-earnings ratio of -4.89 and a beta of 1.63. The business's 50-day simple moving average is $2.22 and its 200-day simple moving average is $2.27.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) last released its earnings results on Thursday, May 15th. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.16). The business had revenue of $2.00 million for the quarter. On average, analysts forecast that Oramed Pharmaceuticals Inc. will post -0.03 earnings per share for the current year.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. BML Capital Management LLC boosted its stake in Oramed Pharmaceuticals by 14.3% during the 1st quarter. BML Capital Management LLC now owns 3,020,748 shares of the biotechnology company's stock worth $6,464,000 after acquiring an additional 376,841 shares during the last quarter. Boothbay Fund Management LLC increased its position in shares of Oramed Pharmaceuticals by 2.0% in the 4th quarter. Boothbay Fund Management LLC now owns 845,188 shares of the biotechnology company's stock valued at $2,045,000 after buying an additional 16,857 shares in the last quarter. Peapod Lane Capital LLC increased its position in shares of Oramed Pharmaceuticals by 11.0% in the 1st quarter. Peapod Lane Capital LLC now owns 252,224 shares of the biotechnology company's stock valued at $540,000 after buying an additional 24,985 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Oramed Pharmaceuticals by 143.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 118,995 shares of the biotechnology company's stock worth $288,000 after buying an additional 70,190 shares during the period. Finally, Jane Street Group LLC lifted its holdings in Oramed Pharmaceuticals by 35.3% during the first quarter. Jane Street Group LLC now owns 67,173 shares of the biotechnology company's stock worth $144,000 after acquiring an additional 17,510 shares in the last quarter. 12.73% of the stock is owned by institutional investors and hedge funds.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.